Cerebrolysin

Human clinical Neuroprotection 3 sources

Cerebrolysin is a complex mixture of low-molecular-weight peptides and amino acids derived from purified porcine brain tissue. Research indicates it mimics the action of endogenous neurotrophic factors, promoting neuroprotection, neurogenesis, and synaptic plasticity. It has been extensively studied and utilized in clinical settings for stroke recovery, traumatic brain injury, and neurodegenerative conditions like Alzheimer's disease.

01Dosing reference

Amount

5-50 mL per day depending on the severity of the condition (e.g., 5 mL IM for mild cognitive issues, up to 50 mL IV for acute stroke)

Frequency

Once daily

Cycle

Typically 10-20 days per cycle, which can be repeated based on clinical response

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Neurotrophic Factor Mimicry

The peptides in Cerebrolysin mimic endogenous neurotrophic factors like BDNF and GDNF, crossing the blood-brain barrier to interact with neuronal receptors.

Neuroprotection and Anti-Excitotoxicity

It reduces excitotoxicity by modulating NMDA receptors and decreases free radical formation, protecting neurons from ischemic or traumatic damage.

Neurogenesis and Plasticity

It stimulates the growth of new neurons and synapses, facilitating brain repair and functional recovery after injury.

03Human evidence

Improved motor and cognitive recovery in acute ischemic stroke patients.

Demonstrated in large randomized controlled trials (e.g., CARS trial) when administered early post-stroke, though some meta-analyses show mixed results on long-term mortality.

Enhanced cognitive function and global clinical impression in Alzheimer's disease and vascular dementia.

Multiple clinical trials show symptomatic improvement, with benefits often persisting for months after the treatment cycle ends.

04Preclinical evidence

Reduced infarct volume and improved neurological outcomes in animal models of stroke.

Consistently observed in rodent models of middle cerebral artery occlusion (MCAO) when given shortly after the ischemic event.

Increased synaptic density and neurogenesis in the hippocampus.

Observed in transgenic mouse models of Alzheimer's disease, correlating with improved spatial memory performance.

05What is known vs. unknown

Reasonably established

Acts as a multimodal neurotrophic drug, mimicking factors like BDNF and NGF.
Extensively studied in human clinical trials for acute ischemic stroke and traumatic brain injury.
Shows efficacy in improving cognitive symptoms in vascular dementia and Alzheimer's disease.
Administered primarily via intramuscular (IM) or intravenous (IV) infusion due to the large volumes required.

Unknowns & limits

The exact active peptide sequences responsible for its effects remain partially undefined due to its nature as a complex biological mixture.
The optimal therapeutic window and long-term disease-modifying effects in progressive neurodegenerative diseases are still debated.
Some large-scale meta-analyses have questioned the robustness of its efficacy in acute stroke compared to standard care alone.

06Safety & regulatory context

Regulatory statusCerebrolysin is generally well-tolerated with a favorable safety profile. Common mild side effects include headache, dizziness, sweating, and a sensation of heat. Because it is derived from porcine brain tissue, there is a theoretical concern regarding prion transmission, though the manufacturing process includes rigorous purification and viral clearance steps that mitigate this risk. It is approved as a prescription medication in many countries across Europe and Asia for neurological conditions, but it is not FDA-approved in the United States.

07Compared with Cortexin

Cerebrolysin vs. Cortexin

Key difference

While both are brain-derived peptide mixtures, Cortexin is typically administered in smaller volumes via intramuscular injection, whereas Cerebrolysin is often given in larger volumes via intravenous infusion for acute conditions.

When researchers discuss each

Researchers discuss Cerebrolysin primarily in the context of acute stroke and TBI recovery with extensive international clinical trial data, while Cortexin is more frequently discussed in Eastern European literature for pediatric developmental delays and general neuroprotection.

08Glossary

Neurotrophic Factor

Proteins that support the growth, survival, and differentiation of both developing and mature neurons.

Excitotoxicity

Nerve damage or death caused by excessive stimulation by neurotransmitters such as glutamate, common in stroke and TBI.

Neurogenesis

The process by which new neurons are formed in the brain.

09Knowledge check

Q1What is the primary mechanism by which Cerebrolysin exerts its neuroprotective effects?

Q2Due to the required dosage volumes, how is Cerebrolysin typically administered for acute conditions?

Q3When interpreting the clinical evidence for Cerebrolysin in acute ischemic stroke, which statement best reflects limitations noted in the dossier?

Q4According to the dossier's direct comparison with Cortexin, which contextual difference is accurate?

Q5Which statement best summarizes the dossier's safety and regulatory context for Cerebrolysin?

10Sources

More in Neuroprotection

See all

Pinealon

Neuroprotection

Early human

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) designed to act as a peptide bioregulator for the brain and central nervous system. Research suggests it interacts directly with DNA to regulate gene expression, offering neuroprotective effects, improving cognitive function, and reducing oxidative stress in brain cells.

1-2 mg per day (SubQ) or 10-20 mg per day (Oral)

ARA-290 (Cibinetide)

Neuroprotection

Human clinical

ARA-290, also known as Cibinetide, is an engineered peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) without stimulating red blood cell production. Research has primarily focused on its potential to reduce inflammation, promote tissue repair, and alleviate neuropathic pain, particularly in conditions like sarcoidosis and diabetic neuropathy.

4 mg/day

Vitamin B12 (Injectable Methylcobalamin)

Neuroprotection

FDA-approved context

Methylcobalamin is the active, coenzyme form of Vitamin B12 that is essential for cell growth, blood formation, and neurological function. Research shows it plays a critical role in DNA synthesis and myelin formation, making it a highly effective treatment for B12 deficiency, pernicious anemia, and various neuropathies.

1000 - 5000 mcg per injection

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.